Gilberto Lopes
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
PURPOSE Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by poor prognosis. The ADRIATIC trial demonstrated significant survival benefits with durvalumab as maintenance therapy for limited-stage SCLC (LS-SCLC). However, the high cost of durvalumab necessitates an evaluation of its cost-effectiveness. METHODS A partitioned survival model was developed to assess the cost-effectiveness of durvalumab consolidation therapy compared with the standard of care (SOC). The model comprised three mutually exclusive health states: progression-free survival (PFS), progression of disease (POD)/metastasis, and death. Incremental cost-effectiveness ratio (ICER) was calculated as cost per quality-adjusted life year (QALY) gained, with a willingness-to-pay (WTP) threshold of $150,000 in US dollars (USD)/QALY. One-way and probabilistic sensitivity analyses were conducted. Analysis for POD was also stratified into intrathoracic, extrathoracic, and CNS. RESULTS Durvalumab improved overall survival (OS) to 66.1 months and PFS to 40.2 months, compared with 57.8 and 31.8 months for SOC, respectively. The total cost of durvalumab was $163,722 USD versus $25,816 USD for placebo, resulting in an incremental cost of $137,905 USD. Durvalumab provided an incremental QALY gain of 0.36 years, yielding an ICER of $383,069 USD/QALY, exceeding WTP. On stratification, durvalumab in patients with extrathoracic progression nearly met WTP (ICER, $151,137 USD). CONCLUSION Durvalumab remains cost-prohibitive for the overall cohort, exceeding acceptable thresholds despite favorable outcomes. Subgroup analysis, however, indicates that selective use in patients with extrathoracic progression may enhance cost-effectiveness. Overcoming economic barriers will be essential for the sustainable integration of immunotherapy into routine care.
Year:
2025
PURPOSE Lung cancer remains a leading cause of cancer mortality in Brazil, with non–small cell lung cancer (NSCLC) accounting for 85% of cases, with 1.6% carrying epidermal growth factor receptor (EGFR) exon 20 mutations. In the phase I CHRYSALIS trial (ClinicalTrials.gov identifier: NCT02609776 ), amivantamab demonstrated a median overall survival (OS) of 22.8 months versus 8.3 months with docetaxel, the standard second-line Brazil's Unified Health System (SUS) therapy. Although the Brazilian Health Regulatory Agency approved amivantamab, the National Commission for the Incorporation of Technologies’ cost-effectiveness reviews result in an average 10-year delay before SUS incorporation. We aimed to estimate premature deaths and life-years lost attributable to this access gap. METHODS Using National Institute of Cancer (INCA) data, we estimated SUS-eligible patients, NSCLC prevalence, and EGFR exon 20 frequency. Stage distribution and 5-year recurrence rates identify candidates for amivantamab. A hazard ratio (HR) was derived from the inverse exponential method (ln(2)/OS ratio). Preventable deaths were calculated as: eligible patients × (1 – HR). Life-years gained per patient were estimated as OS difference. RESULTS Of the 26,548 new patients with lung cancer, 18,973 are SUS-eligible, 16,127 have NSCLC, and 258 have EGFR exon 20 mutations. Metastatic disease accounts for 114, whereas recurrences occur in 60 (stage III), eight (II), and four (I), totaling 186 candidates annually. With an HR of 0.364, the annual preventable death in the base-case scenario is equal to 186 × (1 – 0.364) × 95% = 112 patients. Over 10 years, 1,120 premature deaths and 1,353 life-years could be avoided. CONCLUSION Delayed SUS incorporation of amivantamab may result in over a 1,000 preventable deaths and life-years lost among Brazilian EGFR exon 20–mutated NSCLC. Urgent real-world studies and cost-effectiveness analyses are needed.
Year:
2025
PURPOSE To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and Guardant360 CDx (G360 ctDNA) liquid biopsy for biomarker detection in metastatic nonsquamous non–small cell lung cancer. PATIENTS AND METHODS This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153 ) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA. The primary objective was noninferiority of LHM ctDNA to tissue NGS and G360 ctDNA. Secondary analyses included turnaround time (TAT), overall response rate (ORR), and progression-free survival (PFS), with exploratory analysis of the clinical utility of ctRNA. RESULTS LHM ctDNA (48.2%) detected 11.4% fewer biomarker-positive patients than tissue NGS (59.6%) and did not meet noninferiority criteria. Compared with tissue NGS, LHM ctDNA and G360 ctDNA were concordant in 72.1% and 66.1% of patients, establishing noninferiority of LHM ctDNA to G360 ctDNA ( P = .002). TAT was shorter for LHM ctDNA than for tissue NGS (mean 9.7 v 21.7 days; P < .001). ORR/PFS was similar in patients receiving targeted therapy based on all three assays. Addition of ctRNA increased the diagnostic yield of tissue NGS–confirmed gene rearrangements by 28.6% relative to LHM ctDNA and all actionable biomarkers by 15.6% relative to G360 ctDNA. LHM ctDNA and ctRNA (51/68) detected 8.8% more biomarker-positive patients than G360 ctDNA (45/68), demonstrating superiority of LHM ctDNA and ctRNA ( P = .001). CONCLUSION LHM ctDNA is noninferior to G360 ctDNA, but not tissue NGS. Treatment outcomes based on liquid biopsy are comparable with those based on tissue NGS. Incorporation of ctRNA into LHM ctDNA improves the diagnostic yield of actionable, tissue NGS–confirmed gene rearrangements.
Year:
2025
Patient attrition and NY-ESO-1 and LAGE-1a expression profiles in the multiarm study. A, Patient attrition for multiarm study. A total of 1,698 patients in the multiarm study were screened and signed the informed consent form. Out of 13 dosed patients, six withdrew prior to meeting interventional phase completion criteria, per protocol. B, NY-ESO-1 IHC P -score distribution of screened NY-ESO-1–positive patients in the multiarm study. NY-ESO-1–positive protein expression was detected as a continuous variable with distribution between 10% and 100% expression. There were 62 patients whose tumors expressed NY-ESO-1 with a P score of ≥10%, 1+, 2+, and 3+, with each vertical bar representing a unique tumor sample depicted by contributing IHC intensity of 0+ in blue, 1+ in light blue, 2+ in light orange, and 3+ in orange (425 patients whose tumors expressed NY-ESO-1 C, NY-ESO-1 expression profile of dosed NY-ESO-1–positive patients in the multiarm study. The mITT population based on NY-ESO-1 IHC expression is individually represented in the vertical bars with the P -score broken down by contributing IHC intensity of 0+ in blue, 1+ in light blue, 2+ in light orange, and 3+ in orange. The patients are ordered by P score, which is indicated by the red line. NY-ESO-1–negative, LAGE-1a–positive patients in the mITT population not shown. D, LAGE-1a RNA expression distribution of all tested patients in the multiarm study. The plot of patients tested for LAGE-1a RT-PCR RNA expression, in which the red line indicates the cutoff = 4 ΔCT, with positive cases depicted in red and negative cases depicted in blue. Triangles represent all patients screened. The two patients dosed who were LAGE-1a–positive are distinguished in the figure with a red circle. Patients with “no expression” were imputed as having the lowest observable value divided by 3. The vertical axis is reversed (zero is higher); lower LAGE-1a score measured by RT-PCR represents higher expression levels. E, NY-ESO-1 and LAGE-1a prevalence. This is a bar chart displaying NY-ESO-1 and LAGE-1a prevalence. LAGE-1a testing was performed on tissue samples in reflex to NY-ESO-1–negative status for when tissue was available. Prevalence includes unique samples from the same patient. NE, not evaluable.
Year:
2025
Cellular kinetics profile by patient in the single- and multiarm studies. A, Single-arm study. Cellular kinetics profile at first infusion by patient and responder status truncated at 12 weeks (available data), mITT population. B, Multiarm study. Cellular kinetics profile by patient and treatment arm truncated at 6 months (first infusion), mITT population. AUC 0–28 days, AUC from 0 to 28 days.
Year:
2025
Patient tumor responses in the single- and multiarm studies. A, Best overall response in the single- and multiarm studies (confirmed). In the single-arm study, data following first infusion only. One patient did not have measurable target lesions at baseline and does not appear in this plot; one patient received a transduced cell dose below the required dose level, per protocol, due to waiver granted. In the multiarm study, *arm A: one patient (M65) had unconfirmed PR. **Arm C: one patient (M1) had unequivocal progression due to new lesion and one patient died prior to first post-treatment scan and does not appear in this plot. B, Percent change from baseline in target lesion diameter in the multiarm study. Arm A patients are shown at left, and arm C is shown at right. Red circles indicate new target lesions. C, Median PFS and OS for each study. D, Radiographic images of case study patient S5, single-arm study. One patient from the single-arm study (S5) received two separate infusions, achieving best overall responses of confirmed PR from first infusion and SD from the second, per RECIST 1.1. The top left image is baseline before the first infusion, and top right is after 9 months. The bottom left image is baseline before the second infusion, and the bottom right is at week 11 after second infusion. E, Peak persistence and tumor shrinkage of case study patient S5, single-arm study. CR, complete response; LLOD, lower limit of detection; NA, not available; NE, not evaluable; PD, progressive disease; SD, stable disease.
Year:
2025
Purpose: The study aims to evaluate the safety, tolerability, and antitumor response of letetresgene autoleucel (lete-cel), genetically modified autologous T cells expressing a T-cell receptor specific for New York esophageal squamous cell carcinoma 1 (NY-ESO-1)/LAGE-1a shared epitope, alone or in combination with pembrolizumab, in HLA-A*02–positive (HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06) patients with NY-ESO-1– and/or LAGE-1a–positive non–small cell lung cancer. Patients and Methods: Study 208749 was a single-arm study of lete-cel alone. Study 208471 was a multiarm study of lete-cel alone or in combination with pembrolizumab in patients with advanced or recurrent non–small cell lung cancer. Results: More than 2,500 patients were screened for target expression. In the multiarm study, 738 (45%) of 1,638 tested patients were HLA-A*02–positive. NY-ESO-1 and LAGE-1a testing was positive in 12% (62/525) and 4% (15/348) of tested patients, respectively. Forty-one patients positive for HLA-A*02 and antigen expression were screened in the single-arm study. Overall, 43 patients underwent leukapheresis and 18 received lete-cel across studies. Lete-cel demonstrated a manageable safety profile. No fatal treatment-related serious adverse events (AE) were reported in either study. Cytopenias and cytokine release syndrome were the most common treatment-emergent AEs. Combining pembrolizumab with lete-cel did not seem to increase toxicity over lete-cel alone. Limited antitumor activity was observed; one of 18 patients had a durable response persisting for 18 months. Pharmacokinetic data showed similar T-cell expansion in all patients. Conclusions: Extensive HLA-A*02 and antigen expression testing was performed to identify potential participants. Lete-cel was generally well tolerated and had no unexpected AEs. Antitumor activity was observed in a limited number of patients.
Year:
2025
Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627 patients from six major cancer centers whose tumors underwent molecular testing at Caris Life Sciences between 2010 and 2020. Kaplan–Meier and Cox regression were used to describe and analyze overall survival. The molecular and demographic features of the cohort were analyzed by χ 2 and ANOVA tests. Black patients composed 25% of the cohort and White patients 63%. Among this molecularly-tested cohort, there were minimal outcome differences based on race, geographic location, or poverty level. When analyzing the interaction of age, race, and sex, racial-based disparities were noted primarily for young non-White women in the study cohort but were more pronounced for men and women of all ages in the broader patient population within the Surveillance, Epidemiology, and End Results database. Mutations in five genes— APC , EGFR , STK11 , TP53 , and KRAS —were found to affect overall survival among our cohort, and their prevalence varied by race in specific tumor types. Real-world outcomes data in mutation-defined cohorts also provided additional context to previously reported therapeutic response trends. Our study shows that patients who undergo molecular testing display reduced racial health disparities compared with the general population, whereas persistent racial disparities are influenced by age and sex. Genomic-driven racial disparities should be examined at a tumor lineage-specific level. Increased access to molecular testing for all eligible patients may play a role in improving health equity. Significance: This study is the largest of its kind to analyze health disparities and genomic features among a diverse multiinstitutional cohort of patients who underwent molecular testing. Continuing to increase awareness of and access to molecular testing approaches may help to reduce cancer health disparities and improve outcomes for all patients.
Year:
2025
Analysis of treatment-associated outcomes and effect of mutation status among patients in Caris CODEai clinico-genomic database. A and B, Kaplan–Meier analysis comparing posttreatment OS between patients with STK11 -mutated (mut, blue lines) and STK11 -wild type (wt, red lines) NSCLC treated with ( A ) carboplatin (no pembrolizumab) and ( B ) pembrolizumab (no carboplatin). C and D, Kaplan–Meier analysis comparing ( C ) posttreatment OS and ( D ) TOT between patients treated with pemetrexed (blue lines) and osimertinib (red lines) for EGFR -mut NSCLC. E and F, Kaplan–Meier analysis comparing posttreatment OS between patients with EGFR -mut (blue lines) and EGFR -wt (red lines) NSCLC treated with ( E ) osimertinib or ( F ) pemetrexed. G and H, Kaplan–Meier analysis comparing ( G ) posttreatment OS and ( H ) TOT between patients treated with fluorouracil (blue lines) and capecitabine (red lines) for colorectal cancer.
Year:
2024
Genomic features and clinico-demographic associations of cohort. A, Total number of tumors positive for each mutated gene. B, Percentage of total tumors from each study site for the top 20 most commonly mutated genes. C, Prevalence of co-mutations among APC , EGFR , STK11 , TP53 , and KRAS . Red indicates strong co-mutation whereas blue indicates mutual exclusivity. D, Percentage of indicated tumor types with mutations in APC , EGFR , STK11 , TP53 , and KRAS . E, Age of patients among (−) and (+) gene mutation cohorts. The red line indicates the median age. F, Ratio of males to females in (−) and (+) gene mutation cohorts. G, Percentage of total (−) and (+) cohorts composed by indicated racial groups. *, P P P
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (17)
Jennifer W Carlisle
Winship Cancer Institute of Emory University
Greg Dyson
Professor
Wayne State University
George Sledge
-
Frank Cackowski
Assistant Professor
Karmanos Cancer Institute
Samuel Kareff
University of Miami School of Medicine
Hirva Mamdani
Karmanos Cancer Institute
Martin Edelman
Physician and Chair
Fox Chase Cancer Center
Marjorie Zauderer
Section Chief, Hematology & Medical Oncology
New York Medical College
Mohammed Al Hallak
Assistant Professor
Wayne State University School of Medicine
Mehmet Altan
Associate Professor
The University of Texas MD Anderson Cancer Center
Elisabeth I. Heath
Wayne State University School of Medicine
Ira Winer
Professor
Wayne State University
John V. Heymach
The University of Texas MD Anderson Cancer Center
Heidy N. Medina
University of Miami
Muhammad Furqan
Professor
University of Oklahoma Health Sciences Center
Paulo S. Pinheiro
University of Miami Miller School of Medicine
ENRIQUETA FELIP
Head Thoracic Oncology Unit (After Competitive Exam)
Hospital Universitari Vall d'Hebron
Make your next move.
Prepare your application
Review drafts before you send them.